{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:05:11Z","timestamp":1784109911772,"version":"3.55.0"},"reference-count":129,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed\/platinum-based chemotherapy has been challenged since 2020 by dual immunotherapy, that is, anti-programmed cell death-1 (anti-PD-1) + anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors and recently by combination of chemotherapy + anti-PD-1. However, PM prognosis remains globally poor, without validated curative treatment to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed alternative pre-clinical models and clinical data for the evaluation of new treatments and strategies to optimize response to immunotherapies in pleural mesothelioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Various innovative immunotherapies alone or combined with standard treatments and\/or targeted therapies are currently assessed by clinical trials. The evaluation of these new strategies deserves relevant preclinical models, requiring the use of human models in addition to or even instead of mouse models. These models recapitulate, at least partially, heterogeneity of the tumours and offer new perspectives for the development and evaluation of immunotherapies. However, like all models, they exhibit advantages and disadvantages needing to be identified in order to use them to answer a well-defined biological question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Along with ongoing trials testing innovative immunotherapies and strategies in pleural mesothelioma, original pre-clinical models are required to optimize these strategies and discover new ones for our patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223284","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:20:17Z","timestamp":1771352417000},"page":"806-817","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies"],"prefix":"10.1136","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct04334759","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06155279","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05647265","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04996017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04177953","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05380713","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04926948","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03399552","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02959463","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04334759","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06097728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05918107","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03710876","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04400539","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-3747","authenticated-orcid":false,"given":"Christophe","family":"Blanquart","sequence":"first","affiliation":[{"name":"INSERM UMR 1232, The Regional Center for Research in Cancerology and Immunology Nantes \/ Angers, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-1863","authenticated-orcid":false,"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[{"name":"Pneumology and Thoracic Oncology, CHU de Lille, Lille, France"},{"name":"University of Lille, Lille, France"},{"name":"INSERM U1189, OncoThAI, OncoLILLE, NETMESO, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026071502151573000_81.8.806.1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","article-title":"Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study","volume":"18","author":"Huang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.806.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2026071502151573000_81.8.806.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2026071502151573000_81.8.806.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"2026071502151573000_81.8.806.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30100-1"},{"key":"2026071502151573000_81.8.806.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1912719"},{"key":"2026071502151573000_81.8.806.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01321-1"},{"key":"2026071502151573000_81.8.806.8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"2026071502151573000_81.8.806.9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"2026071502151573000_81.8.806.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6"},{"key":"2026071502151573000_81.8.806.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26143"},{"key":"2026071502151573000_81.8.806.12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"2026071502151573000_81.8.806.13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010019"},{"key":"2026071502151573000_81.8.806.14","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","article-title":"Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma","volume":"14","author":"Giotti","year":"2024","journal-title":"Cancer Discov"},{"key":"2026071502151573000_81.8.806.15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"2026071502151573000_81.8.806.16","article-title":"The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review","volume":"3","author":"Mansfield","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2026071502151573000_81.8.806.17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"2026071502151573000_81.8.806.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"2026071502151573000_81.8.806.19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of Pleural Mesothelioma: ASCO Guideline Update","volume":"43","author":"Kindler","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026071502151573000_81.8.806.20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026071502151573000_81.8.806.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00062-6"},{"key":"2026071502151573000_81.8.806.22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026071502151573000_81.8.806.23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026071502151573000_81.8.806.24","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"2026071502151573000_81.8.806.25","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026071502151573000_81.8.806.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"2026071502151573000_81.8.806.27","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"2026071502151573000_81.8.806.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00471-X"},{"key":"2026071502151573000_81.8.806.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"2026071502151573000_81.8.806.30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/cancers14061498","article-title":"Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study","volume":"14","author":"Assi\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026071502151573000_81.8.806.31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21037\/tlcr-19-686","article-title":"Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program","volume":"9","author":"Cantini","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2026071502151573000_81.8.806.32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743","volume":"167","author":"Scherpereel","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"2026071502151573000_81.8.806.33","doi-asserted-by":"crossref","first-page":"107440","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2026071502151573000_81.8.806.34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.806.35","doi-asserted-by":"crossref","first-page":"107866","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04\u20132021) trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2026071502151573000_81.8.806.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104123","article-title":"Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA","volume":"10","author":"Douma","year":"2025","journal-title":"ESMO Open"},{"key":"2026071502151573000_81.8.806.37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026071502151573000_81.8.806.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01541-0"},{"key":"2026071502151573000_81.8.806.39","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"2026071502151573000_81.8.806.40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"2026071502151573000_81.8.806.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1333661","article-title":"Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream","volume":"14","author":"Calabr\u00f2","year":"2023","journal-title":"Front Immunol"},{"key":"2026071502151573000_81.8.806.42","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026071502151573000_81.8.806.43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026071502151573000_81.8.806.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2566"},{"key":"2026071502151573000_81.8.806.45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13046-025-03314-w","article-title":"A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma","volume":"44","author":"Shi","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2026071502151573000_81.8.806.46","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026071502151573000_81.8.806.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49842-5"},{"key":"2026071502151573000_81.8.806.48","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-22-0886","article-title":"Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma","volume":"13","author":"Danlos","year":"2023","journal-title":"Cancer Discov"},{"key":"2026071502151573000_81.8.806.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2133"},{"key":"2026071502151573000_81.8.806.50","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.athoracsur.2014.12.077","article-title":"Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?","volume":"99","author":"Munck","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2026071502151573000_81.8.806.51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"2026071502151573000_81.8.806.52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-025-01661-x","article-title":"WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome","volume":"18","author":"Berneman","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026071502151573000_81.8.806.53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2169"},{"key":"2026071502151573000_81.8.806.54","article-title":"Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study","volume":"6","author":"Agrawal","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"2026071502151573000_81.8.806.55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112960","article-title":"Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma","volume":"14","author":"Chintala","year":"2023","journal-title":"Front Immunol"},{"key":"2026071502151573000_81.8.806.56","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026071502151573000_81.8.806.57","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107928","article-title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","volume":"195","author":"Mansfield","year":"2024","journal-title":"Lung Cancer"},{"key":"2026071502151573000_81.8.806.58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","article-title":"Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial","volume":"30","author":"Passiglia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026071502151573000_81.8.806.59","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(82)80083-X"},{"key":"2026071502151573000_81.8.806.60","first-page":"3199","article-title":"Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model","volume":"47","author":"Reale","year":"1987","journal-title":"Cancer Res"},{"key":"2026071502151573000_81.8.806.61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2429"},{"key":"2026071502151573000_81.8.806.62","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.351"},{"key":"2026071502151573000_81.8.806.63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1971"},{"key":"2026071502151573000_81.8.806.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.10.039"},{"key":"2026071502151573000_81.8.806.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.015"},{"key":"2026071502151573000_81.8.806.66","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910550331"},{"key":"2026071502151573000_81.8.806.67","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(94)90192-9"},{"key":"2026071502151573000_81.8.806.68","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.165"},{"key":"2026071502151573000_81.8.806.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.12.014"},{"key":"2026071502151573000_81.8.806.70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12943-018-0891-0","article-title":"Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis","volume":"17","author":"Smeele","year":"2018","journal-title":"Mol Cancer"},{"key":"2026071502151573000_81.8.806.71","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0215-RA"},{"key":"2026071502151573000_81.8.806.72","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgz066"},{"key":"2026071502151573000_81.8.806.73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2147\/IJN.S435787","article-title":"Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies","volume":"19","author":"Briolay","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"2026071502151573000_81.8.806.74","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583"},{"key":"2026071502151573000_81.8.806.75","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1200650","article-title":"Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma","volume":"5","author":"Farahmand","year":"2023","journal-title":"Front Toxicol"},{"key":"2026071502151573000_81.8.806.76","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191257","article-title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice","volume":"217","author":"Badhai","year":"2020","journal-title":"J Exp Med"},{"key":"2026071502151573000_81.8.806.77","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-4113"},{"key":"2026071502151573000_81.8.806.78","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202609","article-title":"3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor\u2010on\u2010a\u2010Chip","volume":"12","author":"Li","year":"2023","journal-title":"Adv Healthcare Materials"},{"key":"2026071502151573000_81.8.806.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.12.004"},{"key":"2026071502151573000_81.8.806.80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-2.18045","article-title":"CHEMORESISTANCE RELATED TO HYPOXIA ADAPTATION IN MESOTHELIOMA CELLS FROM TUMOR SPHEROIDS","volume":"44","author":"Endoh","year":"2022","journal-title":"Exp oncol"},{"key":"2026071502151573000_81.8.806.81","doi-asserted-by":"crossref","first-page":"973576","DOI":"10.3389\/fonc.2022.973576","article-title":"3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies","volume":"12","author":"Shi","year":"2022","journal-title":"Front Oncol"},{"key":"2026071502151573000_81.8.806.82","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jtcvs.2015.02.020","article-title":"Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids","volume":"149","author":"Lei","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026071502151573000_81.8.806.83","doi-asserted-by":"crossref","first-page":"14242","DOI":"10.1021\/acsami.7b01737","article-title":"PEGylated Anionic Magnetofluorescent Nanoassemblies: Impact of Their Interface Structure on Magnetic Resonance Imaging Contrast and Cellular Uptake","volume":"9","author":"Linot","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"2026071502151573000_81.8.806.84","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7150\/jca.2.507","article-title":"Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy","volume":"2","author":"Phung","year":"2011","journal-title":"J Cancer"},{"key":"2026071502151573000_81.8.806.85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014640","article-title":"The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy","volume":"6","author":"Xiang","year":"2011","journal-title":"PLoS One"},{"key":"2026071502151573000_81.8.806.86","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s11095-024-03794-z","article-title":"Development and In-Vitro Evaluation of Doxorubicin-Loaded Methacrylate Gelatin (GelMa)-Acrylamide Hydrogels for the Treatment of Malignant Pleural Mesothelioma","volume":"41","author":"Kulkarni","year":"2024","journal-title":"Pharm Res"},{"key":"2026071502151573000_81.8.806.87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039556","article-title":"Changes in Global Gene Expression Associated with 3D Structure of Tumors: An Ex Vivo Matrix-Free Mesothelioma Spheroid Model","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS ONE"},{"key":"2026071502151573000_81.8.806.88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150044","article-title":"Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma","volume":"11","author":"Barbone","year":"2016","journal-title":"PLoS One"},{"key":"2026071502151573000_81.8.806.89","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M709698200"},{"key":"2026071502151573000_81.8.806.90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052753","article-title":"Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression","volume":"7","author":"Barbone","year":"2012","journal-title":"PLoS One"},{"key":"2026071502151573000_81.8.806.91","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.32"},{"key":"2026071502151573000_81.8.806.92","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13530"},{"key":"2026071502151573000_81.8.806.93","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.58","article-title":"The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance","volume":"2","author":"Barbone","year":"2011","journal-title":"Cell Death Dis"},{"key":"2026071502151573000_81.8.806.94","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.18632\/oncotarget.28134","article-title":"Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052\/484 spheroids","volume":"12","author":"Gendre","year":"2021","journal-title":"Oncotarget"},{"key":"2026071502151573000_81.8.806.95","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.124","article-title":"Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors","volume":"6","author":"Echeverry","year":"2015","journal-title":"Cell Death Dis"},{"key":"2026071502151573000_81.8.806.96","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2016.1173799"},{"key":"2026071502151573000_81.8.806.97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005560","article-title":"Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation\/polarization processes between human and mouse macrophages","volume":"10","author":"Monnier","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026071502151573000_81.8.806.98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS One"},{"key":"2026071502151573000_81.8.806.99","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000182","article-title":"Involvement of the M-CSF\/IL-34\/CSF-1R pathway in malignant pleural mesothelioma","volume":"8","author":"Blondy","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026071502151573000_81.8.806.100","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00160210"},{"key":"2026071502151573000_81.8.806.101","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0579"},{"key":"2026071502151573000_81.8.806.102","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0309"},{"key":"2026071502151573000_81.8.806.103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094391","article-title":"Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids","volume":"22","author":"Mola","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026071502151573000_81.8.806.104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076689","article-title":"A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment","volume":"24","author":"Boumya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026071502151573000_81.8.806.105","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0017"},{"key":"2026071502151573000_81.8.806.106","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0993-5"},{"key":"2026071502151573000_81.8.806.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107542"},{"key":"2026071502151573000_81.8.806.108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105355","article-title":"Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6","volume":"25","author":"Cioce","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026071502151573000_81.8.806.109","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-21200-8","article-title":"In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening","volume":"8","author":"Mazzocchi","year":"2018","journal-title":"Sci Rep"},{"key":"2026071502151573000_81.8.806.110","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1362-2","article-title":"Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma","volume":"15","author":"Kalra","year":"2015","journal-title":"BMC Cancer"},{"key":"2026071502151573000_81.8.806.111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0844"},{"key":"2026071502151573000_81.8.806.112","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-022-01129-4","article-title":"Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library","volume":"14","author":"Offin","year":"2022","journal-title":"Genome Med"},{"key":"2026071502151573000_81.8.806.113","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.307"},{"key":"2026071502151573000_81.8.806.114","first-page":"181","article-title":"Transplantation of human malignant mesothelioma into nude mice","volume":"40","author":"Chahinian","year":"1980","journal-title":"Cancer Res"},{"key":"2026071502151573000_81.8.806.115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s10020-024-00835-6","article-title":"FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology","volume":"30","author":"Chan","year":"2024","journal-title":"Mol Med"},{"key":"2026071502151573000_81.8.806.116","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38552-z","article-title":"Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma","volume":"14","author":"Potter","year":"2023","journal-title":"Nat Commun"},{"key":"2026071502151573000_81.8.806.117","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.585079","article-title":"Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"2026071502151573000_81.8.806.118","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-02430-5","article-title":"Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma","volume":"4","author":"Chan","year":"2021","journal-title":"Commun Biol"},{"key":"2026071502151573000_81.8.806.119","doi-asserted-by":"crossref","DOI":"10.3390\/ph13100289","article-title":"Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma","volume":"13","author":"Chia","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026071502151573000_81.8.806.120","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0149"},{"key":"2026071502151573000_81.8.806.121","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90047-0"},{"key":"2026071502151573000_81.8.806.122","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13046-024-03253-y","article-title":"Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma","volume":"43","author":"Salaroglio","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026071502151573000_81.8.806.123","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1021\/acsptsci.4c00324","article-title":"Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review","volume":"7","author":"Ebrahimi","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026071502151573000_81.8.806.124","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1507388","article-title":"Breaking the mold: 3D cell cultures reshaping the future of cancer research","volume":"12","author":"Cordeiro","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026071502151573000_81.8.806.125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175503"},{"key":"2026071502151573000_81.8.806.126","doi-asserted-by":"publisher","DOI":"10.1039\/D3LC00531C"},{"key":"2026071502151573000_81.8.806.127","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03572-7"},{"key":"2026071502151573000_81.8.806.128","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222052"},{"key":"2026071502151573000_81.8.806.129","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222054"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:16:10Z","timestamp":1784106970000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":129,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/thorax-2025-223284"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223284","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}